Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial ki...

Full description

Bibliographic Details
Main Authors: Lawrence G. Lum, Archana Thakur, Abdalla Elhakiem, Lena Alameer, Emily Dinning, Manley Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
bispecific antibody
elotuzumab
activated T cells
OKT3
multiple myeloma
cytotoxicity
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00544/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00544/full

Similar Items